CN102858329B - 用于治疗疾病的化合物 - Google Patents

用于治疗疾病的化合物 Download PDF

Info

Publication number
CN102858329B
CN102858329B CN201180016552.6A CN201180016552A CN102858329B CN 102858329 B CN102858329 B CN 102858329B CN 201180016552 A CN201180016552 A CN 201180016552A CN 102858329 B CN102858329 B CN 102858329B
Authority
CN
China
Prior art keywords
use according
compound
dosage form
epo
hydrazide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180016552.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102858329A (zh
Inventor
A.库宾
P.福特穆勒
G.沃尔伯
D.舒斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Planta Naturstoffe Vertriebsgesmbh
Original Assignee
Planta Naturstoffe Vertriebsgesmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Planta Naturstoffe Vertriebsgesmbh filed Critical Planta Naturstoffe Vertriebsgesmbh
Priority to CN201510244522.0A priority Critical patent/CN104958286B/zh
Publication of CN102858329A publication Critical patent/CN102858329A/zh
Application granted granted Critical
Publication of CN102858329B publication Critical patent/CN102858329B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180016552.6A 2010-01-29 2011-01-28 用于治疗疾病的化合物 Expired - Fee Related CN102858329B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510244522.0A CN104958286B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA122/2010 2010-01-29
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
PCT/AT2011/000050 WO2011091461A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510244522.0A Division CN104958286B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Publications (2)

Publication Number Publication Date
CN102858329A CN102858329A (zh) 2013-01-02
CN102858329B true CN102858329B (zh) 2015-06-17

Family

ID=43707937

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180016552.6A Expired - Fee Related CN102858329B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物
CN201510244522.0A Expired - Fee Related CN104958286B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510244522.0A Expired - Fee Related CN104958286B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Country Status (12)

Country Link
US (1) US20130065962A1 (https=)
EP (2) EP2528595B1 (https=)
JP (1) JP5788907B2 (https=)
KR (1) KR20120128644A (https=)
CN (2) CN102858329B (https=)
AT (1) AT509045B1 (https=)
AU (1) AU2011208939B2 (https=)
BR (1) BR112012018772A2 (https=)
CA (1) CA2788326A1 (https=)
MX (1) MX2012008815A (https=)
SG (1) SG182786A1 (https=)
WO (1) WO2011091461A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022923A1 (en) * 2012-08-10 2014-02-13 Mcmaster University Antibacterial inhibitors
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
KR20170066614A (ko) * 2014-10-10 2017-06-14 프로메틱 파마 에스엠티 리미티드 당뇨병의 예방 및 치료를 위한 치환된 방향족 화합물 및 약제학적 조성물
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
KR102939715B1 (ko) * 2021-03-31 2026-03-17 셰브런 오로나이트 컴퍼니 엘엘씨 저속 사전 점화 이벤트를 완화하기 위한 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
ES2104938T3 (es) 1991-04-01 1997-10-16 Univ Duke Metodo de inhibir la fibrosis.
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO2000015215A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
WO2000073280A1 (en) 1999-05-28 2000-12-07 Cheil Jedang Corporation Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
EP1603858A2 (en) 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
US7514470B2 (en) 2004-03-03 2009-04-07 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EA022445B1 (ru) * 2009-05-04 2016-01-29 Прометик Байосайенсиз Инк. Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Beri ripla 等.synthesis and antitubercular activity of N-aryl- glycylhydrazides.《proceedings of the indian national science academy. PART A. physical sciences》.1991,第57卷(第05期),第645-654页. *
synthesis and antitubercular activity of N-aryl- glycylhydrazides;Beri ripla 等;《proceedings of the indian national science academy. PART A. physical sciences》;19911231;第57卷(第05期);第645-654页，表Ⅱ *

Also Published As

Publication number Publication date
BR112012018772A2 (pt) 2016-04-12
JP5788907B2 (ja) 2015-10-07
CN104958286A (zh) 2015-10-07
AU2011208939A1 (en) 2012-08-30
CA2788326A1 (en) 2011-08-04
MX2012008815A (es) 2012-11-23
KR20120128644A (ko) 2012-11-27
AT509045B1 (de) 2011-06-15
AT509045A4 (de) 2011-06-15
CN102858329A (zh) 2013-01-02
WO2011091461A1 (de) 2011-08-04
CN104958286B (zh) 2018-01-05
EP2528595B1 (de) 2015-08-05
US20130065962A1 (en) 2013-03-14
AU2011208939B2 (en) 2015-07-09
EP2965755A1 (de) 2016-01-13
JP2013518061A (ja) 2013-05-20
SG182786A1 (en) 2012-09-27
EP2528595A1 (de) 2012-12-05

Similar Documents

Publication Publication Date Title
Donnelly et al. Therapy for chronic obstructive pulmonary disease in the 21st century
US20220001014A1 (en) Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
CN102858329B (zh) 用于治疗疾病的化合物
KR20160125283A (ko) 레보세티리진 및 몬테루카스트의 혈관염의 치료 용도
JP2023134592A (ja) ライノウイルス感染症の予防又は治療のための薬物
CN101969944B (zh) 脂肪性肝病的治疗用医药组合物
US20100240736A1 (en) Novel Compounds for the Treatment or Alleviation of Edema, and Methods for their Use
CN103200955A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
KR20150138848A (ko) 레보세티리진 및 몬테루카스트의 과민증 치료 용도
RU2727142C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
KR20240035919A (ko) 신규한 글루타미닐 고리화효소 억제제 및 다양한 질환의 치료에서의 이의 용도
US11439631B2 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
NZ532019A (en) Anti-influenza drugs
KR20230018474A (ko) 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법
WO2021209620A1 (en) Cysteine protease inhibitors for use in the prevention and/or treatment of coronavirus
US8003704B2 (en) Methods and compositions for the treatment of alcoholism and alcohol dependence
CN119632984B (zh) 蝙蝠葛苏林碱在制备髓过氧化物酶抑制剂及治疗急性肺损伤药物中的应用
JP7497868B2 (ja) アンジオテンシン変換酵素２の発現抑制剤、および、アンジオテンシン変換酵素２を受容体とするウイルスに対する抗ウイルス剤
CN118717780A (zh) 土大黄苷在制备防治类风湿关节炎的药物中的应用
HK40028225B (zh) 戊二酰亚胺衍生物用於治疗与细胞因子的异常活性相关的疾病的用途
CN113230255A (zh) 阿帕替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用
CN101014369A (zh) 利用cox—2选择性抑制剂和ltb4受体拮抗剂的组合用于治疗炎症和疼痛的组合物
JPWO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150617

Termination date: 20200128